Treating elevated intraocular pressure with nicotinamide and its analogs

This technology is a therapeutic approach that uses a low dose of nicotinamide to lower intraocular pressure (IOP), which, when elevated, is an important risk factor for glaucoma.

Unmet Need: Prophylactic therapy for the prevention of glaucoma

Glaucoma affects millions globally and can be caused by the buildup of intraocular pressure (IOP), causing optic nerve damage and progressive blindness. Because glaucoma is often detected after damage occurs, it is critical to monitor and reduce high IOP when first detected. Current treatments focus on reducing high IOP through topical eye application, which is difficult and time-consuming for patients. Therefore, there is a need for a cost-effective and easy-to-use preventative approach to reduce high IOP with minimal side effects.

The Technology: Nicotinamide-based therapy for treating high intraocular pressure

This technology identifies low doses of nicotinamide for the treatment of high intraocular pressure (IOP) and the prevention of glaucoma development. Nicotinamide can be taken orally in food or drink for easy administration. Low doses of nicotinamide can increase aqueous humor drainage and reduce IOP, which are critical factors in glaucoma progression.

This technology has been validated in preclinical models, demonstrating efficacy in reducing IOP and preserving vision, even in genetic glaucoma predispositions.

Applications:

  • Prophylactic treatment of glaucoma
  • Oral medicine for high intraocular pressure
  • Anti-aging therapy
  • Preventative supplement for age-related eye disease

Advantages:

  • Targets underlying causes of glaucoma
  • Enables preventative treatment
  • Dual efficacy
  • Oral delivery
  • Non-invasive

Lead Inventor:

Simon John, Ph.D.

Patent Information:

Patent Pending (WO/2024/243081)

Tech Ventures Reference: